Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EPS (Weighted Average and Diluted) (2022 - 2025)

Praxis Precision Medicines has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$3.51 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$3.51 for Q4 2025, down 17.0% from a year ago — trailing twelve months through Dec 2025 was -$13.47 (down 30.4% YoY), and the annual figure for FY2025 was -$13.48, down 32.03%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$3.51 at Praxis Precision Medicines, down from -$3.36 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PRAX hit a ceiling of -$0.96 in Q3 2022 and a floor of -$65.86 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 4 years was -$2.92 (2024), compared with a mean of -$7.26.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 97.02% in 2023, while the deepest fall reached 600.66% in 2023.
  • Praxis Precision Medicines' EPS (Weighted Average and Diluted) stood at -$65.86 in 2022, then soared by 97.02% to -$1.96 in 2023, then plummeted by 53.06% to -$3.0 in 2024, then dropped by 17.0% to -$3.51 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$3.51 (Q4 2025), -$3.36 (Q3 2025), and -$3.31 (Q2 2025) per Business Quant data.